Q-omics provides the consensus-scored LRRC17 profile across patient tissues and cancer cell-line models. LRRC17 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, LRRC17 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, LRRC17 RNA expression shows 19,265 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight ACC, KIRC, and BRCA as cancer lineages where LRRC17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC17 survival associations across molecular data types. LRRC17 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC17 RNA expression–survival associations across cancer types. High LRRC17 expression shows unfavorable associations in ACC, KIRP, BLCA, OV and UVM, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for LRRC17 RNA expression.
This table summarizes LRRC17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for LRRC17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC17 shows lower tumor expression in KICH, COAD and KIRP and higher tumor expression in KIRC, HNSC and LUAD. The KIRC box plot shows higher LRRC17 RNA expression in tumor versus normal tissue (log2 FC = +1.202, t-test p < 0.001).
This table shows molecular features associated with LRRC17 in patient tissues and cancer cell lines. In patient samples, LRRC17 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and SOFT_TISSUE.
